Etoposide for Treating the Hypereosinophilic Syndrome
Authors: Emmanuelle Bourrat
Journal: Annals of Internal Medicine (1994)

Letters1 December 1994Etoposide for Treating the Hypereosinophilic SyndromeEmmanuelle Bourrat, Celest Lebbe, and Fabien CalvoEmmanuelle BourratHopital Saint Louis, 75010 Paris, France., Celest LebbeHopital Saint Louis, 75010 Paris, France., and Fabien CalvoHopital Saint Louis, 75010 Paris, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-11-199412010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Smit and colleagues [1] reported encouraging results with etoposide in one case of the hypereosinophilic syndrome. We report our long-term experience using etoposide to treat two patients with the syndrome.Patient 1, a 50-year-old man, developed symptoms of the syndrome in 1984, including an elevated absolute eosinophil count (range, 1800 to 8000 cells/mm3); pruritic, erythematous, scaly eruption; cytolytic hepatitis; and eosinophilic infiltration of the pulmonary system, parotid gland, and bone marrow. Prednisolone (1.5 mg/kg of body weight per day) was started in November 1984 with a good initial response but could not be tapered to less than ...References1. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991; 67:2826-7. Google Scholar2. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BA. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982; 97:78-92. Google Scholar Author, Article, and Disclosure InformationAuthors: Emmanuelle Bourrat; Celest Lebbe; Fabien CalvoAffiliations: Hopital Saint Louis, 75010 Paris, France. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWorld Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and managementWorld Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and managementEosinophilic Disorders: Differential Diagnosis and ManagementSuccessful Treatment of Refractory Idiopathic Hypereosinophilic Syndrome With EtoposideEosinophilic disorders: Molecular pathogenesis, new classification, and modern therapyThe FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementEosinophile Dermatosen und SyndromeCough, Shortness of Breath, and Eosinophilia in a 68-Year-Old ManHypereosinophilic Syndrome 1 December 1994Volume 121, Issue 11Page: 899-900 ePublished: 15 August 2000 Issue Published: 1 December 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...